MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Up 0.5% – Here’s Why

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA)’s share price rose 0.5% on Monday . The stock traded as high as $1.98 and last traded at $1.98. Approximately 582,924 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 1,270,098 shares. The stock had previously closed at $1.97.

MAIA Biotechnology Trading Up 0.5%

The firm has a market capitalization of $73.32 million, a P/E ratio of -2.71 and a beta of -0.07. The company has a 50-day moving average of $1.70 and a 200-day moving average of $1.53.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings results on Friday, November 7th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.08). Research analysts predict that MAIA Biotechnology, Inc. will post -1.3 EPS for the current year.

Insider Buying and Selling

In other news, Director Ngar Yee Louie purchased 81,699 shares of the company’s stock in a transaction dated Monday, December 22nd. The shares were purchased at an average price of $1.22 per share, for a total transaction of $99,672.78. Following the transaction, the director owned 1,248,888 shares of the company’s stock, valued at approximately $1,523,643.36. This trade represents a 7.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Stan Smith acquired 57,189 shares of the firm’s stock in a transaction dated Monday, December 22nd. The shares were purchased at an average price of $1.22 per share, with a total value of $69,770.58. Following the completion of the transaction, the director owned 1,421,478 shares of the company’s stock, valued at $1,734,203.16. This trade represents a 4.19% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have acquired 349,122 shares of company stock valued at $402,193. Insiders own 32.32% of the company’s stock.

Hedge Funds Weigh In On MAIA Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of MAIA. Geode Capital Management LLC grew its holdings in MAIA Biotechnology by 9.5% during the 4th quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock worth $454,000 after acquiring an additional 25,684 shares during the period. Centric Wealth Management lifted its stake in shares of MAIA Biotechnology by 2.0% in the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock valued at $897,000 after purchasing an additional 11,500 shares during the period. Ritholtz Wealth Management bought a new stake in shares of MAIA Biotechnology during the 4th quarter valued at about $35,000. Jane Street Group LLC acquired a new stake in MAIA Biotechnology during the second quarter worth approximately $52,000. Finally, Marshall Wace LLP acquired a new stake in MAIA Biotechnology during the second quarter worth approximately $29,000. Institutional investors and hedge funds own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.